Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Vx3 Imaging PC

Neither a doctor nor a teaching hospital

Research payments

$1,218,406

442 payments

Through program year 2025, Vx3 Imaging PC is reported as receiving $1,218,406 in research payments, across 442 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $169,145 61
2024 Research $108,884 35
2023 Research $228,993 47
2022 Research $181,310 37
2021 Research $189,301 101
2020 Research $125,884 83
2019 Research $214,889 78

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca UK Limited $537,944 28 payments
  2. AbbVie, Inc. $193,665 229 payments
  3. Acerta Pharma LLC $190,508 9 payments
  4. Pharmacyclics LLC, An AbbVie Company $127,865 54 payments
  5. GlaxoSmithKline, LLC. $52,065 23 payments
  6. TESARO, Inc. $35,050 11 payments
  7. Hoffmann-La Roche Limited $34,345 10 payments
  8. Janssen Research & Development, LLC $15,605 21 payments
  9. Novartis Pharma AG $10,290 12 payments
  10. Verastem, Inc. $8,650 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation $268,269 7 payments
  2. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $207,091 11 payments
  3. A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (MATTERHORN) $72,240 4 payments
  4. This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC $60,147 4 payments
  5. A Randomized, Multicenter, Open-Label, Phase?3 Study to Evaluate the Efficacy and Safety of Acalabrutinib versus Chlorambucil plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic Leukemia $44,700 5 payments
  6. A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma $44,185 6 payments
  7. A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-042, An An $41,545 19 payments
  8. A Phase III Study in Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Brafwt Melanoma Patients $34,345 10 payments
  9. Pcyc-1142-Ca $31,635 11 payments
  10. Pcyc-1142-Ca $28,015 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record